Zoetis Inc. (ZTS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ZTS Revenue Growth
Revenue Breakdown (FY 2025)
ZTS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ZTS Revenue Analysis (2014–2025)
As of May 7, 2026, Zoetis Inc. (ZTS) generated trailing twelve-month (TTM) revenue of $9.47 billion, reflecting modest growth of +3.0% year-over-year. The most recent quarter (Q4 2025) recorded $2.39 billion in revenue, down 0.5% sequentially.
Looking at the longer-term picture, ZTS's 5-year compound annual growth rate (CAGR) stands at +7.2%, indicating steady revenue expansion. The company achieved its highest annual revenue of $9.47 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows ZTS's business is primarily driven by Horses (68%), Cattle (16%), and Swine (5%). With over half of revenue concentrated in Horses, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ELAN (+10.5% YoY), PCRX (+4.6% YoY), and PAHC (+32.4% YoY), ZTS has underperformed the peer group in terms of revenue growth. Compare ZTS vs ELAN →
ZTS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ZTSCurrent | $9.5B | +3.0% | +7.2% | 38.0% | |
 ELAN | $4.7B | +10.5% | +7.6% | 5.3% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% | |
 IDXX | $4.3B | +13.1% | +9.7% | 31.6% | |
 NEOG | $895M | -3.7% | +16.4% | 1.1% |
ZTS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $9.47B | +2.3% | $6.67B | 70.5% | $3.60B | 38.0% |
| 2024 | $9.26B | +8.3% | $6.40B | 69.1% | $3.39B | 36.6% |
| 2023 | $8.54B | +5.7% | $5.83B | 68.3% | $3.07B | 35.9% |
| 2022 | $8.08B | +3.9% | $5.48B | 67.8% | $2.93B | 36.2% |
| 2021 | $7.78B | +16.5% | $5.31B | 68.3% | $2.80B | 36.0% |
| 2020 | $6.67B | +6.6% | $4.46B | 66.8% | $2.27B | 34.0% |
| 2019 | $6.26B | +7.5% | $4.11B | 65.7% | $2.02B | 32.2% |
| 2018 | $5.83B | +9.8% | $3.80B | 65.2% | $1.88B | 32.3% |
| 2017 | $5.31B | +8.6% | $3.44B | 64.9% | $1.73B | 32.5% |
| 2016 | $4.89B | +2.6% | $3.14B | 64.3% | $1.40B | 28.7% |
Full ZTS Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ZTS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZTS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZTS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonZTS — Frequently Asked Questions
Quick answers to the most common questions about buying ZTS stock.
Is ZTS's revenue growth accelerating or slowing?
ZTS revenue growth slowed to +3.0%, below the 5-year CAGR of +7.2%. TTM revenue is $9.5B. The deceleration marks a shift from historical growth rates.
What is ZTS's long-term revenue growth rate?
Zoetis Inc.'s 5-year revenue CAGR of +7.2% reflects the variable expansion pattern. Current YoY growth of +3.0% is near this long-term average.
How is ZTS's revenue distributed by segment?
ZTS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.